Cargando…

Preparation, characterization and in vitro–in vivo evaluation of bortezomib supermolecular aggregation nanovehicles

BACKGROUNDS: Intolerable toxicity and unsatisfactory therapeutic effects are still big problems retarding the use of chemotherapy against cancer. Nano-drug delivery system promised a lot in increasing the patients’ compliance and therapeutic efficacy. As a unique nano-carrier, supermolecular aggrega...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Ming-yue, Xiao, Ze-kuan, Lei, Xue-ping, Li, Jie-xia, Yu, Xi-yong, Zhang, Jian-ye, Ye, Guo-dong, Guo, Yu-juan, Mo, Guangquan, Li, Chu-wen, Zhang, Yu, Zhang, Ling-min, Lin, Zhi-qiang, Fu, Ji-jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7118915/
https://www.ncbi.nlm.nih.gov/pubmed/32245495
http://dx.doi.org/10.1186/s12951-020-00612-7
Descripción
Sumario:BACKGROUNDS: Intolerable toxicity and unsatisfactory therapeutic effects are still big problems retarding the use of chemotherapy against cancer. Nano-drug delivery system promised a lot in increasing the patients’ compliance and therapeutic efficacy. As a unique nano-carrier, supermolecular aggregation nanovehicle has attracted increasing interests due to the following advantages: announcing drug loading efficacy, pronouncing in vivo performance and simplified production process. METHODS: In this study, the supermolecular aggregation nanovehicle of bortezomib (BTZ) was prepared to treat breast cancer. RESULTS: Although many supermolecular nanovehicles are inclined to disintegrate due to the weak intermolecular interactions among the components, the BTZ supermolecules are satisfying stable. To shed light on the reasons behind this, the forces driving the formation of the nanovehicles were detailed investigated. In other words, the interactions among BTZ and other two components were studied to characterize the nanovehicles and ensure its stability. CONCLUSIONS: Due to the promising tumor targeting ability of the BTZ nanovehicles, the supermolecule displayed promising tumor curing effects and negligible systemic toxicity.